Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06314711
Other study ID # Ex Vivo US for OPC
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2021
Est. completion date February 1, 2024

Study information

Verified date March 2024
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with biopsy-verified oropharyngeal squamous cell carcinoma or Human Papillomavirus (HPV)-positive unknown primary treated with transoral robotic surgery are included. Immediately post-operatively, freshly resected specimens are examined with ex vivo 3D ultrasound (US). Ex vivo 3D US will be used to match US slices of the specimen with corresponding histopathology slices. The US slices will be reviewed by a panel of head and neck surgeons blinded to histopathology. The primary aim is to explore perioperative ex vivo 3D US for oropharyngeal tumor detection, delineation from normal tissue, tumor size and volume, and margin assessment.


Description:

The purpose of the study is to determine the accuracy of ex vivo 3D ultrasound (US) for detecting and delineating tumor tissue of the tonsils and base of tongue post-operatively. This is a quick technique that may provide valuable information for the surgeon that can potentially improve treatment outcomes. Placing the surgical specimen in a water bath allows for an US swipe to be performed without compressing the specimen. This reduces the deformation of the specimen by removing the pressure from conventional US scanning. A video clip can be captured by swiping across the specimen in the water bath. By motorizing this motion, the video can be converted into a 3D volume due to the known number of video frames and a constant swiping speed. We will correlate the ex vivo 3D US scans to histopathology for the following analyses: - Four surgeons blinded to histopathology will rate each included case in terms of tumor visibility on ex vivo 3D US scans. If visible, the surgeons will mark the tumor and the healthy tissue. - Tumor and margins will be correlated to histopathology pre- and post-formalin fixation on a subset of cases to explore the proportion of tissue shrinkage from formalin fixation. - Two methods of estimating tumor volume will be compared: the ellipsoidal formula and full 3D segmentation.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date February 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients surgically treated with transoral robotic surgery for oropharyngeal squamous cell carcinoma or HPV-positive unknown primary. Exclusion Criteria: - No primary tumor found on final histopathology.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Ultrasound
High-frequency ultrasound of ex vivo specimen

Locations

Country Name City State
Denmark Dept. of Otorhinolaryngology, Head & Neck Surg, Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Makouei F, Agander TK, Ewertsen C, Sondergaard Svendsen MB, Norling R, Kaltoft M, Hansen AE, Rasmussen JH, Wessel I, Todsen T. 3D Ultrasound and MRI in Assessing Resection Margins during Tongue Cancer Surgery: A Research Protocol for a Clinical Diagnostic Accuracy Study. J Imaging. 2023 Aug 28;9(9):174. doi: 10.3390/jimaging9090174. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Fresh ex vivo US Tumor detection (blinded to histopathology) Whether the tumor is visible on US (binary yes/no and 5-point scale from 1: very low certainty - 5 very high certainty) 5 minutes
Primary Margin assessment (blinded to histopathology) Whether the tumor is removed with negative margins (yes / no) 5 minutes
Primary Fresh ex vivo US tumor volume (blinded to histopathology) Measured with ellipsoid volume (mm^3) 5 minutes
Primary Fresh ex vivo US margin distance (blinded to histopathology) Smallest and mean margins measured in mm. 5 minutes
Primary Fresh ex vivo tumor visible on specimen mecrophoto (blinded to histopathology) Whether the tumor is visible clinically by inspecting the macrophoto. 5 minutes
Secondary Fresh ex vivo US tumor volume (unblinded to histopathology) Measured with ellipsoid volume and segmentation (mm^3) 1 day
Secondary Formalin-fixed ex vivo US tumor volume (unblinded to histopathology) Measured with ellipsoid volume and segmentation (mm^3) 1 day
Secondary Fresh ex vivo US margin distance (unblinded to histopathology) Smallest and mean margins measured in mm. 1 day
Secondary Formalin-fixed ex vivo US margin distance (unblinded to histopathology) Smallest and mean margins measured in mm. 1 day
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06174428 - Validity of Viome's Oral/Throat Cancer Test
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Suspended NCT03952585 - De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer Phase 2/Phase 3
Terminated NCT03618134 - Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Phase 1/Phase 2
Recruiting NCT03421470 - Docetaxel and Radiation Therapy in Treating Patients With HPV Positive Oropharynx Cancer Phase 3
Completed NCT04572100 - Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer Phase 1
Not yet recruiting NCT06055868 - People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Recruiting NCT05522881 - The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan
Recruiting NCT04222543 - Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging Phase 2
Recruiting NCT04564989 - Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Active, not recruiting NCT04965792 - Post-treatment Surveillance in HPV+ Oropharyngeal SCC
Recruiting NCT06356272 - Oropharynx (OPX) Biomarker Trial
Active, not recruiting NCT01874171 - Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC Phase 3
Recruiting NCT05333523 - Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. Phase 3
Completed NCT03618654 - Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Early Phase 1
Recruiting NCT04801472 - Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) N/A
Active, not recruiting NCT03410615 - Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC Phase 2
Recruiting NCT05268614 - Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05582590 - Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers Phase 1
Completed NCT02072148 - The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL) N/A